Close

Incyte (INCY) PT Bumped to $115 at Leerink as Gilead's (GILD) Momelotinib Disappoints

Go back to Incyte (INCY) PT Bumped to $115 at Leerink as Gilead's (GILD) Momelotinib Disappoints

Gabelli & Company Highlights 6 Potential Gilead Sciences (GILD) Takeover Targets

November 18, 2016 11:27 AM EST

Following Gilead Sciences' (NASDAQ: GILD) setback with its JAK 1/2 inhibitor momelotinib in myelofibrosis, Gabelli & Company analyst Jing He said she anticipates the company could be interested in buying someone else in oncology or rare disease.

In oncology, the analyst highlighted:

Incyte (NASDAQ:... More

Incyte (INCY) Seen Back of Gilead's (GILD) Takeover Target List Following Disappointing Momelotinib Data - Leerink

November 17, 2016 8:24 AM EST

Leerink Partners analyst Geoffrey Porges says Incyte (NASDAQ: INCY) is back on the list of Gilead Sciences' (NASDAQ: GILD) takeover targets after Gilead's disappointing phase III data for their JAK 1/2 inhibitor momelotinib in myelofibrosis.

"One consequence of this disappointment, however, is that it does restore INCY to the list of... More

Incyte (INCY) PT Lifted to $126 at BMO Capital Following Competitor Set-Back

November 17, 2016 6:42 AM EST

BMO Capital analyst M. Ian Somaiya reiterated an Outperform rating and bumped his price target on Incyte (NASDAQ: INCY) to $126.00 (from $121.00) as mixed data from Gilead's Phase 3 trials of momelotinib in myelofibrosis remove the only source of meaningful competition in the forseeable... More